RVL Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RVL Pharmaceuticals plc
Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
- Generic Drugs
- Specialty Pharmaceuticals
- Controlled Release
- Other Names / Subsidiaries
- Lilydale Limited
- RevitaLid, Inc.
- Osmotica Pharmaceutical Corp
- Osmotica Pharmaceuticals Limited
- Osmotica Pharmaceutical, Plc. RVL Pharmaceuticals Inc..
- Vertical Pharmaceuticals, Inc.
- Vertical / Trigen Holdings, LLC